Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1.69 Bn in 2023, and is expected to exhibit a CAGR of 31.1% by 2030. Mr. Shah Coherent Market Insights Pvt. Ltd.

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

An acute necrotising myopathy is a distinct form of uncommon muscle disease characterised by the rapid advancement of ...

Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN ...

Lexeo Therapeutics, Inc.’s LXEO share price has surged by 50.92%, which has investors questioning if this is right time to ...

Alnylam (ALNY) announced the FDA approval of the supplemental New Drug Application for its RNAi therapeutic, Amvuttra, for the treatment of the ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care ...

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis ...

We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a ...